Emory Winship receives $11M NCI grant to improve immunotherapy for lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Winship Cancer Institute of Emory University was awarded a P01 program project grant from NCI to support research aimed at improving the effectiveness of immunotherapy for lung cancer in patients with a mutation of the LKB1 gene, a group for whom present immunotherapy options do not provide robust benefit. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
MAIA Biotechnology Inc. and BeiGene entered into a clinical supply agreement to assess the efficacy of THIO, MAIA Biotechnology’s small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor tislelizumab, in three cancer indications. The single-arm pivotal phase II trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login